Status:
TERMINATED
Immune Response to SARS-CoV-2 Vaccination in Systemic Lupus
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Systemic Lupus
Eligibility:
All Genders
18+ years
Brief Summary
The main objective is to study the impact of vaccination against Covid-19 on the specific humoral and cellular immune response (against SARS-CoV-2) and non-specific (evolution of the pathological immu...
Eligibility Criteria
Inclusion
- Adult subject (≥ 18 years old), male or female
- Patient with systemic lupus according to ACR 1997 criteria
- Patient followed by the National Reference Center "Rare Systemic Autoimmune Diseases" of the University Hospitals of Strasbourg
- Patient who agreed to be vaccinated against SARS-CoV-2
- Subject having expressed his non-opposition to the research
- Subject affiliated to a social health insurance protection scheme
Exclusion
- Patient treated by:
- Corticosteroids (\> = 10mg / day)
- Immunosuppressant (azathioprine, mycophenolate mofetil, cyclophosphamide) to control lupus activity
- A biomedicine targeting B cells (rituximab, belumimab).
- Inability to provide informed information about the subject (subject in an emergency, difficulty in understanding the subject, etc.)
- Subject under safeguard of justice
- Subject under guardianship
Key Trial Info
Start Date :
June 7 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 22 2023
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT04894253
Start Date
June 7 2021
End Date
December 22 2023
Last Update
December 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Hautepierre
Strasbourg, Bas-Rhin, France, 67000